(Q37084157)

18 August 2017

1 reference

title

Neurotoxic side-effects of cisplatin (English)

1 reference

18 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

3 December 2022

author name string

F. P. Harmers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827334

3 December 2022

W. H. Gispen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827334

3 December 2022

J. P. Neijt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1827334

3 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1827334

3 December 2022

publication date

1 January 1991

1 reference

full work available at URL

18 August 2017

https://api.elsevier.com/content/article/PII:027753799190549S?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

https://api.elsevier.com/content/article/PII:027753799190549S?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

European Journal of Cancer

3 December 2022

published in

1 reference

18 August 2017

27

1 reference

18 August 2017

3

1 reference

18 August 2017

372-376

1 reference

Frequency of neurological disease in a cancer hospital

18 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Complete remission of paraneoplastic sensorimotor neuropathy: a case associated with small-cell lung cancer responsive to chemotherapy, plasma exchange, and radiotherapy

3 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Spinal cord toxicity complicating treatment with cisplatin and etoposide

3 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Cerebral herniation in patients receiving cisplatin

3 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Peripheral sensory neuropathy and cisplatin chemotherapy

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

3 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Quantitative sensory testing demonstrates that subclinical sensory neuropathy is prevalent in patients with cancer

3 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Evolution of high-dose cisplatin

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma

3 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Progressive paresthesias after cessation of therapy with very high-dose cisplatin

3 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer

3 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

3 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro

3 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of the neuroprotecting peptide ORG.2766.

3 December 2022

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

High-dose cisplatin with sodium thiosulfate protection.

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Phase I/II trials of WR-2721 and cis-platinum

3 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer

3 December 2022

19

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity

3 December 2022

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protection

3 December 2022

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Clinical trials of WR-2721 and cis-platinum

3 December 2022

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line

3 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent

3 December 2022

24

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer

3 December 2022

25

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

ACTH accelerates recovery of neuromuscular function following crushing of peripheral nerve

3 December 2022

26

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Effects of corticotrophin (ACTH) on recovery of sensorimotor function in the rat: Structure-activity study

3 December 2022

27

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats

3 December 2022

28

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.

3 December 2022

29

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

3 December 2022

30

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer

3 December 2022

33

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90549-S

3 December 2022

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1827334

3 December 2022

1 reference